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Introduction: Germline Bcl-2-like protein 11 (BIM) deletion poly-
morphism in Asian is a poor predictive factor for treatment outcomes 
to tyrosine kinase inhibitors (TKIs) in malignancies. We explored 
the impact of BIM deletion polymorphism on treatment outcome of 
advanced non–small-cell lung cancer (NSCLC).
Methods: We prospectively collected tissue samples, blood, and 
clinical data from two cohorts of advanced NSCLC patients. BIM 
deletion polymorphism was correlated with overall survival (OS) and 
progression-free survival (PFS) to epidermal growth factor receptor 
(EGFR) TKIs and chemotherapy treatment.
Results: BIM deletion polymorphism was detected in blood of 16.2% 
(33 of 204) patients. The PFS to first-line EGFR-TKIs in 153 patients 
were 8.6 and 4.6 months for patients with wild-type BIM and BIM 
deletion polymorphism, respectively (p = 0.004). Among 120 patients 
who received chemotherapies, the PFS to chemotherapies were 5.6 
and 3.5 months for patients with wild-type BIM and BIM deletion 
polymorphism, respectively (p = 0.050). The OS of all 204 patients 
was 24.8 and 16.8 months for patients with wild-type BIM and BIM 
deletion polymorphism, respectively (p = 0.005). Multivariate analy-
ses suggested that BIM deletion polymorphism was an independent 
predictor for shorter PFS to EGFR-TKIs (hazard ratio [HR] 2.15, 
p = 0.002), PFS to chemotherapy (HR 2.40, p = 0.016), and OS 
(HR 1.65, p = 0.039).
Conclusions: BIM deletion polymorphism predicts shorter PFS to 
EGFR-TKIs and OS in advanced NSCLC.
Key Words: Non–small-cell lung cancer, BIM deletion polymor-
phism, Prognosis
(J Thorac Oncol. 2014;9: 1385–1392)
Lung cancer is the leading cause of cancer related death in the world, and non–small-cell lung cancer (NSCLC) 
accounts for most lung cancers.1 Systemic chemotherapy is 
standard of care for advanced NSCLC. Epidermal growth fac-
tor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such 
as gefitinib, erlotinib, and afatinib, are widely used to treat 
advanced NSCLC harboring mutant EGFR gene2–5 and erlo-
tinib is used for advanced NSCLC in the subsequent lines 
after chemotherapy.6
A deletion polymorphism of Bcl-2-like protein 11 (also 
named as BIM) is observed in 12.8% Asian population and was 
not detected in Caucasian population.7 BIM encodes a BH3 
only protein and activates cell death by either opposing the pro-
survival members of the BCL2 family or by binding to the pro-
apoptotic BCL2 family members and directly activating their 
proapoptotic functions.8,9 BIM is crucial for gefitinib-induced 
apoptosis in lung cancer cells harboring mutant the EGFR 
gene10 and MEK inhibitor-induced apoptosis in lung cancer 
cells carrying wild-type EGFR gene.11 Faber et al.12 demon-
strated that expression of BIM mRNA predicts the capacity 
of EGFR inhibitors but not chemotherapy to induce apoptosis 
in EGFR mutant cancer cells, and low BIM mRNA expres-
sion in EGFR mutant lung cancer specimens is associated with 
shorter progression-free survival (PFS) to EGFR-TKIs thera-
pies. Whereas expression of BIM is unrelated to chemotherapy 
sensitivity, pretreatment BIM mRNA expression is associated 
with treatment response to tyrosine kinase inhibitors in EGFR 
mutant, HER2 amplified, or PIK3CA mutant cancers.12
Recently, Ng et al.7 demonstrated that BIM deletion 
polymorphism results in truncation of the BH3 domain of 
BIM and is related to shorter PFS of imatinib in patients with 
chronic myeloid leukemia. Ng et al.7 further demonstrated 
retrospectively that BIM deletion polymorphism is associ-
ated with shorter PFS to EGFR-TKIs in patients with EGFR 
mutant NSCLC. However, the impact of BIM deletion poly-
morphism on conventional chemotherapy is unknown. Here 
we explored the impact of BIM deletion polymorphism on 
treatment outcome to EGFR-TKIs and chemotherapies.
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PATIENTS AND METHODS
Patient Population and Collection 
of Tumor and Blood Specimens
Ng et al.7 observed a PFS of 11.9 months and 6.6 
months for EGFR mutation-positive patients who received 
EGFR-TKI in BIM wild-type and BIM deletion groups. 
12.8% of Asian patients had BIM deletion polymorphism. 
Under these assumption with a two-tail α of 0.05 and power at 
0.8, 27 patients with BIM deletion polymorphism are required 
to evaluate the effect of BIM deletion polymorphism on PFS 
to EGFR-TKI. A total of 211 patients are needed for a rea-
sonable retrospective analysis. For one tail analysis with the 
assumption that BIM deletion polymorphism has deleterious 
effect on PFS, about half of the patients are required.
We prospectively collected tumor samples, patients’ 
blood, and clinical data in two independent cohorts of advanced 
NSCLC patients, defined as stage IIIB disease with malignant 
pleural effusion or stage IV disease according to the American 
Joint Committee on Cancer version 6. Cohort 1 is a phase II 
study conducted between 2006 and 2008 to evaluate gefi-
tinib efficacy as first-line treatment in stage IIIB/IV NSCLC 
patients13 (ClinicalTrials.gov Identifier: NCT00173875). 
In short, 106 newly diagnosed good performance NSCLC 
patients were enrolled. They were treated with daily 250 mg 
of gefitinib until progression. Patients who had progression 
on gefitinib were recommended to receive second-line che-
motherapy if they were in good performance status (Eastern 
Cooperative Oncology Group [ECOG] 0, 1, or 2). The eligible 
and consented patients signed another informed consent and 
received second-line chemotherapies with either cisplatin-
based doublet or single agent chemotherapies according to 
primary physicians’ decisions. The recommended second-
line treatments were listed in Supplemental Table S1 (SDC 
1, http://links.lww.com/JTO/A611). Second-line chemothera-
pies were discontinued upon a maximum of six-cycle treat-
ment, disease progression as documented by imaging studies, 
or development of intolerable toxicity. One-hundred and one 
patients consented to donate their blood, including germline 
DNA from mononuclear cell, for research.
Cohort 2 is a prospectively observational study 
for advanced NSCLC patients in the National Taiwan 
University Hospital since 2008 (ClinicalTrials.gov Identifier: 
NCT00977509). One-hundred and thirty-two advanced NSCLC 
patients who were expected to survival more than 3 months, 
had measurable diseases and received systemic treatment were 
enrolled. Patients were followed up with regular assessment of 
tumor response until death. Patients who consented to donate 
their mononuclear cells and DNA for research and who enrolled 
before first treatment was included in the analysis.
The analysis of treatment efficacies to EGFR-TKI or 
chemotherapy and the amended evaluation of BIM deletion 
polymorphism using the stored peripheral blood mononu-
clear cell DNA sample was approved by the Research Ethics 
Committee of the National Taiwan University Hospital.
Efficacy Evaluation
PFS was defined from start of treatment to documenta-
tion of progressive disease or death, and overall survival (OS) 
was defined from the date of first-line therapy on diagnosis of 
advanced disease to death.
For patients in the cohort 1, the PFS and OS were deter-
mined by an independent reviewer as described previously in 
the phase II study13 and were updated as of June 2013.
For patients in the cohort 2, computed tomography 
scan were performed every 12 weeks or when clinically indi-
cated for patients who were under first-line therapies and for 
patients who received second-line chemotherapy. The Response 
Evaluation Criteria in Solid Tumor version 1.0 was used to eval-
uate measurable lesions. Serial computed tomography scans 
were retrospectively reviewed by an independent radiologist 
(Dr. Yun-Chung Chang) to determine the date of progression.
Evaluation of EGFR Mutation in Tumors and 
BIM Deletion Polymorphism in Blood
EGFR mutational status of these patients was performed 
as reported previously.13 For evaluation of BIM deletion poly-
morphism, DNA was extracted from peripheral blood mononu-
clear cells using QIAmp DNA blood mini kit (Qiagen, Venlo, 
Netherlands). Evaluation of BIM deletion polymorphism was 
performed using a polymerase chain reaction assay as previ-
ously described.7 The forward primer for wild-type allele was 
CCACCAATGGAAAAGGTTCA and the reverse primer was 
CTGTCATTTCTCCCCACCAC. The forward primer for the 
deletion allele was CCACCAATGGAAAAGGTTCA and the 
reverse primer was GGCACAGCCTCTATGGAGAA. GoTaq 
Hot Start Dashed polymerase was used for polymerase chain 
reaction (Promega, Madison, WI), and the thermo cycling con-
dition was as followed: 95°C for 5 minutes, 39 cycles of (95°C 
for 50 seconds, 58°C for 50 seconds, and 72°C for 1 minute), 
and 72 °C for 10 min. Genomic DNA from the HCC2279 lung 
cancer cell and KCL22 leukemia cell were used as positive 
control (kindly provided by Dr. S Tiong Ong from the Duke–
National University of Singapore Graduate Medical School, 
Singapore). The genomic DNA from the PC-9 cells was used 
as negative control.
Statistical Analysis
All categorical variables were analyzed with χ2 tests, 
except where a small size (n < 5) required the use of Fisher’s 
exact test. Student t test was used to compare age between 
groups. Survivals were analyzed using Kaplan-Meiers’ 
method. The survival differences between different subset 
of patients were compared using log-rank test. The impact 
of BIM deletion polymorphism on survival was further ana-
lyzed in a multivariate analysis using Cox proportional hazard 
ratio model; existence of BIM deletion polymorphism, histol-
ogy of tumors, stage of disease as defined by American Joint 
Committee on Cancer version 6, gender, age, and EGFR muta-
tional status were enrolled in the multivariable analysis. Two-
sided p value < 0.05 was considered statistically significant.
RESULTS
Patient Characteristics
Two-hundred and four patients were enrolled in the cur-
rent analysis; 153 patients for analysis of PFS to EGFR-TKIs, 
1387Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014 BIM Deletion in Advanced Lung Cancer
and 120 patients for analysis of PFS to chemotherapy 
(Supplemental Figure S1, SDC 1, http://links.lww.com/JTO/
A611). Table 1 depicts the patient characteristics of both 
cohorts. There were 80 (39.2%) men and 124 (60.8%) women, 
and 152 (74.5%) patients were never smokers; 189 (92.6%) 
tumors were adenocarcinomas and seven patients’ perfor-
mance status were ECOG 2 on enrollment. EGFR gene was 
studied in 155 (76.0%) tumors and mutant EGFR gene was 
detected in 101 (65.2%) tumors studied.
BIM deletion polymorphism was detected in 33 (16.2%) 
patients. BIM deletion polymorphism was unrelated to clinical 
characteristics of patients with the exception of more patients 
with BIM deletion polymorphism had stage IIIB disease 
(Table 2). BIM deletion polymorphism was unrelated to the 
EGFR mutational status of tumors.
BIM Deletion Polymorphism on Treatment 
Outcome of First-Line EGFR-TKIs
One hundred and one patients from cohort 1 (all 
received gefitinib) and 52 patients from cohort 2 (34 gefitinib, 
12 erlotinib, and 6 afatinib) received EGFR-TKIs as first-line 
therapy. Seventy eight (51.0%) patients achieved at least par-
tial response to EGFR-TKIs. BIM deletion polymorphism was 
unrelated to treatment response to EGFR-TKIs (Table 2).
As of June 2013, 138 (90.2%) progressive diseases or 
deaths were recorded. The median PFS to first-line EGFR-TKIs 
was 8.1 months (95% confidence interval 7.0–9.1 months). As 
expected, the PFS to first-line EGFR-TKIs were longer in patients 
carrying mutant EGFR tumors (9.1 months) than patients car-
rying wild-type EGFR tumors (3.5 months; p < 0.001, Fig. 1A). 
We observed shorter PFS to EGFR-TKIs treatment in patients 
with BIM deletion (Fig. 1B, p = 0.004,). In subgroup analysis 
according to the EGFR mutation status in tumors, BIM dele-
tion polymorphism predicted significant shorter PFS in tumors 
carrying wild-type EGFR gene (Fig. 1C) and a nonsignificant 
trend of shorter PFS in tumors carrying common EGFR muta-
tions (Fig.1D). The PFS for the seven ECOG two patients was 
2.8 months and was significantly shorter than other ECOG 0–1 
patients (p < 0.001). A multivariate analysis suggested BIM 
deletion polymorphism and EGFR mutational status were inde-
pendent predictive factors for PFS (hazard ratio [HR] = 2.15, 
p = 0.002 and 0.36, p < 0.001, respectively; Table 3).
BIM Deletion Polymorphism on Treatment 
Outcome of Chemotherapies
As BIM is proapoptotic, we studied whether BIM dele-
tion polymorphism affected treatment outcome to chemo-
therapy. Supplemental Tables S2 and S3 (SDC 1, http://links.
lww.com/JTO/A611) depict the chemotherapies given to the 
69 patients from cohort 1 (chemotherapies on failure to first-
line EGFR-TKI therapy) and the 51 patients from cohort 2 
(first-line chemotherapy), respectively. Forty four (63.8%) 
patients in the cohort 1 and 40 (78.4%) patients in the cohort 2 
received platinum-based doublet chemotherapies. The median 
cycles of chemotherapies were four (1–12) in cohort 1 and 
five (1–18) in cohort 2. Ninety nine out of all 120 patients 
(82.5%) received at least 3 cycles of chemotherapies. In total, 
TABLE 1.  Patient Characteristics
Characteristic Cohort 1 Cohort 2 p Valuea
101 103
Age (year) Mean 63.6 61.5 0.31
Gender Male 35 45 0.20
Female 66 58
Smoking status Current/former 29 23 0.78
Never 72 80
Pathology Adenocarcinoma 92 97 0.25
Non-adenocarcinoma 8 4
Non-specified 1 2
AJCC stage IIIB 10 2 0.01
IV 91 101
EGFR Wild type 33 22 0.32b
Mutation present 52 49
del 19 or L858R 41 45
Other mutations 11 4
Not performed 16 33
BIM Wild type 84 87 0.85
Deletion 17 16
aTwo-sides p-value by χ2 test with the exception of age, which was compared by t test.
bComparison between presence of mutation and Bcl-2-like protein 11 (BIM) 
polymorphism.
EGFR, epidermal growth factor receptor; AJCC, American Joint Committee on 
Cancer.
TABLE 2.  Relationship Between Bcl-2-Like Protein 11 (BIM) 
Deletion Polymorphism and Clinical Characteristics
Wild Type Deletion p valuea
171 33
Age (year) Mean 61.7 66.7 0.43
Gender Male 65 15 0.44
Female 106 18
Pathology Adenocarcinoma 159 30 0.70
Non-adenocarcinoma 11 1
Non-specified 1 2
AJCC stage IIIB 8 5 0.04
IV 163 28
EGFR Wild type 44 11 0.83b
Mutation present 83 18
del 19 or L858R 69 17
Other mutations 14 1
Not performed 44 4
Response to 
EGFR-TKIs  
(n = 153)
CR + PR 68 10 0.09
SD + PD 50 16
Non-evaluable 8 1
Response to 
chemotherapy 
(n = 120)
CR + PR 19 2 0.52
SD + PD 74 15
Non-evaluable 9 1
aTwo-sided p value by χ2 test with the exception of age, which was compared by t test.
bComparison between presence of mutation and BIM polymorphism.
TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; AJCC, 
American Joint Committee on Cancer; CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease.
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21 patients (17.5%) achieved at least partial response to che-
motherapies, 10 (14.5%) in the cohort 1, and 11 (21.6%) in 
the cohort 2. BIM deletion polymorphism was unrelated to 
treatment response (Table 2).
The PFS to chemotherapies in cohort 1 and cohort 
2 were 5.7 months and 4.5 months, respectively (p = 0.91; 
Fig. 2A). The OS from first-line of therapy on diagnosis of 
advanced NSCLC were 23.8 months for the 69 patients in the 
cohort 1 and 25.7 months for the 51 patients in the cohort 2 
(p = 0.84). The PFS to chemotherapies of patients carrying 
wild-type BIM and BIM deletion polymorphism were 5.6 and 
3.5 months, respectively (p = 0.050; Fig. 2B). We observed a 
trend of longer PFS to chemotherapy in female patients; the 
PFS to chemotherapies for male and female patients were 5.0 
FIGURE 1.  Kaplan-Meiers’ curves of progression-free survival (PFS) to first-line epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors. A, PFS by wild-type EGFR (solid line, n = 40) or mutant EGFR (dashed line, n = 80); (B) PFS by 
wild-type BIM (solid line, n = 126) or BIM deletion polymorphism (dashed line, n = 27). (C) In wild-type EGFR tumors, PFS by 
wild-type BIM (solid line, n=30) or BIM deletion polymorphism (dashed line, n = 10). (D) In mutant EGFR tumors, PFS by wild-
type BIM (solid line, n = 64) or BIM deletion polymorphism (dashed line, n = 16). wt, wild-type; mt, mutant; del, deletion; verti-
cal bars, censored values.
TABLE 3.  Multivariate Analysis
PFS to EGFR-TKI PFS to Chemotherapy OS
Variable HR p Value 95% CI HR p Value 95% CI HR p Value 95% CI
BIM deletion 2.15 0.002 1.32–3.51 2.40 0.016 1.17–4.90 1.65 0.039 1.02–2.66
EGFR mutation 0.36 <0.001 0.23–0.56 1.48 0.106 0.92–2.37 0.66 0.033 0.45–0.97
Non-adenocarcinoma 2.08 0.048 1.01–4.29 2.00 0.530 0.23–17.43 1.90 0.081 0.92–3.90
Female gender 0.97 0.879 0.63–1.48 0.59 0.032 0.37–0.96 0.98 0.922 0.66–1.45
Age > 60 year old 0.77 0.213 0.51–1.16 1.08 0.744 0.68–1.71 1.28 0.200 0.88–1.88
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor.
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months and 5.4 months, respectively (p = 0.052; Fig. 2C). 
EGFR mutations were evaluated in 93 (77.5%) tumors, and 
the PFS of wild-type and mutant EGFR tumors were 5.8 and 
4.4 months (p = 0.49) (Fig. 2D). A multivariate analysis sug-
gested that BIM deletion polymorphism independently pre-
dicted shorter PFS to chemotherapy (HR 2.4, p = 0.016) and 
female gender predicted independently longer PFS to chemo-
therapy (HR: 0.59, p = 0.032).
BIM Deletion Polymorphism on OS
As BIM deletion polymorphism predicts shorter PFS to 
both EGFR-TKIs and chemotherapies, we explored whether 
BIM deletion polymorphism influences OS of patients with 
advanced NSCLC. As of June, 2013, 156 of 204 patients 
(76.5%) died. The median OS was 23.4 months (95% confi-
dence interval: 19.9–26.9 months). There was a trend in favor 
of longer OS in patients carrying EGFR mutant tumors by 
log-rank test (p = 0.056; Fig. 3A). The OS for patients carry-
ing wild-type BIM and BIM deletion polymorphism were 24.8 
months and 16.8 months (p = 0.005,. In subgroup analysis, no 
OS difference was observed between wild-type BIM and BIM 
deletion polymorphism group according to the mutational sta-
tus of the EGFR gene in tumors (Fig. 3C, D). The OS for the 
seven ECOG 2 patients was 4.8 months and was significantly 
shorter than other ECOG 0–1 patients (p < 0.001). A multi-
variate analysis suggested that BIM deletion polymorphism 
and presence of mutant EGFR gene were independent pre-
dictor for OS (HR1.65, p = 0.039 and HR 0.66, p = 0.033, 
respectively; Table 3).
DISCUSSION
In this study, we confirmed that BIM deletion poly-
morphism was independently associated with shorter PFS 
to EGFR-TKIs in advanced NSCLC patients. Furthermore, 
BIM deletion polymorphism was associated with shorter PFS 
to chemotherapy in multivariate analysis, and BIM deletion 
polymorphism independently predicts shorter OS of advanced 
NSCLC.
Several biomarkers are related to treatment effect of 
EGFR-TKIs, whereas very few biomarkers are associated with 
OS of advanced NSCLC patients. Previous reports and our 
current study (Fig. 1A) suggested mutant EGFR gene in the 
FIGURE 2.  Kaplan-Meiers’ curves of progression-free survival (PFS) to chemotherapy. A, PFS in cohort 1 (chemotherapy on fail-
ure to first-line EGFR-tyrosine kinase inhibitor; solid line, n = 69) and cohort 2 (dashed line, first-line chemotherapy; n = 51). (B) 
PFS by wild-type BIM (solid line, n = 102) or BIM deletion polymorphism (dashed line, n = 18). (C) PFS by male patients (solid 
line, n = 50) or female patients (dashed line, n = 70). (D) PFS by wild-type epidermal growth factor receptor (EGFR; solid line,  
n = 36) or mutant EGFR (dashed line, n = 57). wt, wild-type; mt, mutant; del, deletion; vertical bars, censored values.
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tumors is independently associated with longer PFS to EGFR-
TKIs, and the idea was further supported by the meta-analy-
sis showing that EGFR-TKIs prolong PFS in mutant EGFR 
NSCLC but not wild-type EGFR NSCLC.14 Su et al.15 dem-
onstrated that pretreatment EGFR T790M mutation in tumors 
was associated with shorter PFS of lung adenocarcinoma 
patients receiving EGFR-TKIs therapy, and Ng et al.7 recently 
reported that BIM deletion polymorphism was a predictive 
biomarker for EGFR-TKI therapy in advanced lung adenocar-
cinoma carrying mutant EGFR genes. We observed a trend in 
favor of shorter PFS to EGFR-TKIs in patients with mutant 
EGFR advanced lung cancer. We further demonstrated that 
BIM deletion polymorphism independently predicts shorter 
OS of advanced NSCLC patients (Fig. 3B and Table 3). Our 
findings suggest that BIM deletion polymorphism should be 
considered as a stratification factor when systemic treatment 
is considered in Asian NSCLC patients.
We observed that BIM deletion polymorphism was 
related to shorter PFS to EGFR-TKIs in patients with wild-
type EGFR NSCLC. Eight of 40 (20%) patients with wild-
type EGFR NSCLC responded to EGFR-TKI in our study, 
and all eight patients carried wild-type BIM. Although EGFR-
TKIs are inferior to chemotherapies in patients with wild-type 
EGFR NSCLC, patients may benefit from EGFR-TKIs com-
paring with placebo. For example, 7% patients with wild-type 
EGFR NSCLC responded to erlotinib in the BR21 trial. In 
addition, as EGFR mutational status was determined by direct 
sequencing in our study, we do not exclude the possibility that 
false-negative result of the EGFR gene sequencing may con-
tribute to the observation in our study.
Lung adenocarcimas in East-Asians are characterized 
by frequent mutations of oncogenic drivers, especially the 
EGFR gene.16 Sun et al.16 reported that 78.8% of lung adeno-
carcinomas from never smokers carried mutant EGFR gene. 
Shi et al.17 recently evaluated EGFR mutations in 1482 East 
Asia lung adenocarcinomas and observed that EGFR muta-
tions were detected in 51.4% of all 1482 adnocarcinomas, 
and 62.1% of tumors from Taiwan and 64.2% of tumors from 
Vietnam. Here, we reported that mutant EGFR gene was 
detected in 101 of 152 (65.2%) tumors in our analysis. As 
189 (92.6%) tumors in our analysis were adenocarcinomas 
and 152 (74.5%) patients were never smokers (Table 1), the 
FIGURE 3.  Kaplan-Meiers’ curves of overall survival (OS). A, OS by wild-type epidermal growth factor receptor (EGFR; solid 
line, n = 55) or mutant EGFR (dashed line, n = 101); (B) OS by wild-type BIM (solid line, n = 171) or BIM deletion polymorphism 
(dashed line, n = 33). (C) In wild-type EGFR tumors, OS by wild-type BIM (solid line, n = 44) or BIM deletion polymorphism 
(dashed line, n = 11). (D) In mutant EGFR tumors, OS by wild-type BIM (solid line, n = 83) or BIM deletion polymorphism 
(dashed line, n = 18). wt, wild-type; mt, mutant; del, deletion; vertical bars, censored values.
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frequency of mutant EGFR gene in our analysis was compa-
rable with other East Asian studies reported previously.
With the introduction of EGFR-TKIs, the response rate 
to EGFR-TKI in EGFR mutant lung adenocarcinomas were 
54.0% to 84.6%,18 and the median survival of advanced lung 
cancer patients in East Asia was 17.4 to 27.7 months.6,19,20 
Costa et al.21 recently reported that, in a randomized phase 
III trial for frontline erlotinib therapy in European patients 
carrying EGFR mutant lung adenocarcinomas, the OS were 
22.1 to 22.9 months, and patients with tumors expressing 
high BIM mRNA survived longer than those with tumors 
expressing low/intermediate BIM mRNA (28.6 months ver-
sus 22.1 months p = 0.0364). The 51.0% response rate to 
EGFR-TKIs and the median OS of 23.4 months in our anal-
ysis were consistent with prospective randomized studies 
addressing the effect of EGFR-TKIs in advanced NSCLC.19–
21 Because of the low frequency of EGFR mutation and 
extreme rare BIM deletion polymorphism in Caucasian pop-
ulation, the result of this research may only be applicable to 
East Asian population.
It was reported that vorinostat, an HDAC inhibitor, 
overcame EGFR-TKI resistance, in vitro and in vivo, in EGFR 
mutant NSCLC cell lines harboring BIM deletion polymor-
phism.17 Little is known whether anti-apoptotic agent such as 
obatoclax is able to overcome the resistance to EGFR-TKIs 
resulting from BIM deletion polymorphism. It is warranted to 
explore strategies to overcome the resistance clinically.
It was proposed that chemotherapies kill susceptible 
cancer cells by apoptosis.22 Li et al.23 demonstrated that BIM, 
but not Bcl-2, mediates apoptosis induced by paclitaxel in 
breast cancer and NSCLC cells. Here, we observed a strong 
trend of shorter PFS to chemotherapy in patients harboring 
BIM deletion polymorphism (p = 0.050; Fig. 2B). We also 
reported a significant impact of BIM deletion polymorphism 
on PFS to chemotherapy (HR 2.40, p = 0.016; Table 3).
In the cohort 1 of the current study, we reported the 
result of a phase II trial evaluating the impact of first-line gefi-
tinib in treatment-naïve Asian NSCLC patients. 69 of the 106 
enrolled patients (67.3%) received second-line chemotherapy. 
All patients were prospectively followed for their second-
line and subsequent treatment. In this prospective analysis, 
we demonstrated the median PFS of the second-line chemo-
therapy was 5.7 months in advanced NSCLC patients who 
had failed first-line gefitinib therapy, and the overall response 
rate was 14.5%. The PFS of 5.7 months the survival time 
was comparable to the survivals of EGFR wild-type NSCLC 
patients receiving chemotherapies as first-line chemotherapy,4 
and we did not observed difference of PFS to first-line che-
motherapy (cohort 2) and chemotherapy on failure to EGFR-
TKIs (cohort 1; Fig. 2A). Prior exposure to EGFR-TKIs may 
have little impact on the effect of subsequent chemotherapy. 
Prospective studies to find out the response rates and PFS of 
chemotherapy after failure to first-line EGFR-TKI in EGFR 
mutation-positive patients are being conducted (e.g., clinical-
trials.gov NCT01544179).
In conclusion, BIM deletion polymorphism is an inde-
pendent predictive factor for PFS to EGFR-TKIs and OS of 
advanced NSCLC. BIM deletion polymorphism should be 
considered in design clinical trials of EGFR mutation-positive 
patients in Asia in the future.
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